<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:16:06Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8078262" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8078262</identifier>
        <datestamp>2022-03-20</datestamp>
        <setSpec>jco</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Clin Oncol</journal-id>
              <journal-id journal-id-type="hwp">jco</journal-id>
              <journal-id journal-id-type="pmc">jco</journal-id>
              <journal-id journal-id-type="publisher-id">JCO</journal-id>
              <journal-title-group>
                <journal-title>Journal of Clinical Oncology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0732-183X</issn>
              <issn pub-type="epub">1527-7755</issn>
              <publisher>
                <publisher-name>Wolters Kluwer Health</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8078262</article-id>
              <article-id pub-id-type="pmcid">PMC8078262</article-id>
              <article-id pub-id-type="pmc-uid">8078262</article-id>
              <article-id pub-id-type="pmid">33529058</article-id>
              <article-id pub-id-type="pmid">33529058</article-id>
              <article-id pub-id-type="publisher-id">JCO.20.02365</article-id>
              <article-id pub-id-type="doi">10.1200/JCO.20.02365</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>ORIGINAL REPORTS</subject>
                  <subj-group>
                    <subject>Genitourinary Cancer</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2675-5095</contrib-id>
                  <name>
                    <surname>McDermott</surname>
                    <given-names>David F.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff1">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="corresp" rid="cor1"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9420-7162</contrib-id>
                  <name>
                    <surname>Lee</surname>
                    <given-names>Jae-Lyun</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff2">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6870-9492</contrib-id>
                  <name>
                    <surname>Ziobro</surname>
                    <given-names>Marek</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="aff3">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Suarez</surname>
                    <given-names>Cristina</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="aff4">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Langiewicz</surname>
                    <given-names>Przemyslaw</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff5">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7748-9527</contrib-id>
                  <name>
                    <surname>Matveev</surname>
                    <given-names>Vsevolod Borisovich</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="aff6">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wiechno</surname>
                    <given-names>Pawel</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="aff7">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7592-0392</contrib-id>
                  <name>
                    <surname>Gafanov</surname>
                    <given-names>Rustem Airatovich</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="aff8">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tomczak</surname>
                    <given-names>Piotr</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="aff9">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pouliot</surname>
                    <given-names>Frederic</given-names>
                  </name>
                  <degrees>MD, PhD, FRCSC</degrees>
                  <xref ref-type="aff" rid="aff10">
                    <sup>10</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8449-863X</contrib-id>
                  <name>
                    <surname>Donskov</surname>
                    <given-names>Frede</given-names>
                  </name>
                  <degrees>MD, DMSc</degrees>
                  <xref ref-type="aff" rid="aff11">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Alekseev</surname>
                    <given-names>Boris Yakovlevich</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff12">
                    <sup>12</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shin</surname>
                    <given-names>Sang Joon</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="aff13">
                    <sup>13</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6903-5357</contrib-id>
                  <name>
                    <surname>Bjarnason</surname>
                    <given-names>Georg A.</given-names>
                  </name>
                  <degrees>MD, FRCPC</degrees>
                  <xref ref-type="aff" rid="aff14">
                    <sup>14</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Castellano</surname>
                    <given-names>Daniel</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff15">
                    <sup>15</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Silverman</surname>
                    <given-names>Rachel Kloss</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="aff16">
                    <sup>16</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Perini</surname>
                    <given-names>Rodolfo F.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff16">
                    <sup>16</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5106-3082</contrib-id>
                  <name>
                    <surname>Schloss</surname>
                    <given-names>Charles</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff16">
                    <sup>16</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Atkins</surname>
                    <given-names>Michael B.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff17">
                    <sup>17</sup>
                  </xref>
                </contrib>
                <aff id="aff1"><label><sup>1</sup></label>Beth Israel Deaconess Medical Center, Boston, MA</aff>
                <aff id="aff2"><label><sup>2</sup></label>Asan Medical Center and University of Ulsan College of Medicine, Seoul, South Korea</aff>
                <aff id="aff3"><label><sup>3</sup></label>Centrum Onkologii-Instytut im. Marii Sklodowskiej, Cracow, Poland</aff>
                <aff id="aff4"><label><sup>4</sup></label>Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain</aff>
                <aff id="aff5"><label><sup>5</sup></label>Wojskowy Instytut Medyczny Centralny Szpital Medyczny MON, Warszawa, Poland</aff>
                <aff id="aff6"><label><sup>6</sup></label>N.N. Blokhin Russian Cancer Research Center, Moscow, Russia</aff>
                <aff id="aff7"><label><sup>7</sup></label>Narodowy Instytut Onkologii-Państwowy Instytut Badawczy im. Marii Skłodowskiej-Curie, Warsaw, Poland</aff>
                <aff id="aff8"><label><sup>8</sup></label>Russian Scientific Center of Roentgenoradiology, Moscow, Russia</aff>
                <aff id="aff9"><label><sup>9</sup></label>Clinical Hospital No. 1 of the Poznan University of Medical Sciences, Poznań, Poland</aff>
                <aff id="aff10"><label><sup>10</sup></label>CHU de Quebec and Laval University, Quebec City, QC, Canada</aff>
                <aff id="aff11"><label><sup>11</sup></label>Aarhus University Hospital, Aarhus, Denmark</aff>
                <aff id="aff12"><label><sup>12</sup></label>P. A. Herzen Moscow Oncology Research Institute, Ministry of Health of the Russian Federation, Moscow, Russia</aff>
                <aff id="aff13"><label><sup>13</sup></label>Yonsei University College of Medicine, Seoul, South Korea</aff>
                <aff id="aff14"><label><sup>14</sup></label>Sunnybrook Odette Cancer Centre, Toronto, ON, Canada</aff>
                <aff id="aff15"><label><sup>15</sup></label>Hospital Universitario 12 de Octubre, I +12 Research Institute, Madrid, Spain</aff>
                <aff id="aff16"><label><sup>16</sup></label>Merck &amp; Co, Inc, Kenilworth, NJ</aff>
                <aff id="aff17"><label><sup>17</sup></label>Georgetown Lombardi Comprehensive Cancer Center, Washington, DC</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1">David F. McDermott, MD, Chief of Medical Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Kirstein 207, Boston, MA 02215; e-mail: <email>dmcdermo@bidmc.harvard.edu</email>.</corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <day>20</day>
                <month>3</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>02</day>
                <month>2</month>
                <year>2021</year>
              </pub-date>
              <volume>39</volume>
              <issue>9</issue>
              <fpage>1029</fpage>
              <lpage>1039</lpage>
              <history>
                <date date-type="received">
                  <day>30</day>
                  <month>7</month>
                  <year>2020</year>
                </date>
                <date date-type="rev-recd">
                  <day>22</day>
                  <month>10</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>30</day>
                  <month>11</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2021 by American Society of Clinical Oncology</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>American Society of Clinical Oncology</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p>
                </license>
              </permissions>
              <self-uri xlink:href="jco-39-1029.pdf"/>
              <abstract>
                <title>PURPOSE</title>
                <p>Programmed death 1 (PD-1) pathway inhibitors have not been prospectively evaluated in patients with non–clear cell renal cell carcinoma (nccRCC). The phase II KEYNOTE-427 study (cohort B) was conducted to assess the efficacy and safety of single-agent pembrolizumab, a PD-1 inhibitor, in advanced nccRCC.</p>
                <sec>
                  <title>METHODS</title>
                  <p>Patients with histologically confirmed, measurable (Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) nccRCC and no prior systemic therapy received pembrolizumab 200 mg intravenously once every 3 weeks for ≤ 24 months. The primary end point was objective response rate (ORR) per RECIST v1.1.</p>
                </sec>
                <sec>
                  <title>RESULTS</title>
                  <p>Among enrolled patients (N = 165), 71.5% had confirmed papillary, 12.7% had chromophobe, and 15.8% had unclassified RCC histology. Most patients (67.9%) had intermediate or poor International Metastatic RCC Database Consortium risk status and tumors with programmed death ligand 1 (PD-L1) combined positive score (CPS) ≥ 1 (61.8%). The median time from enrollment to database cutoff was 31.5 months (range, 22.7-38.8). In all patients, the ORR was 26.7%. The median duration of response was 29.0 months; 59.7% of responses lasted ≥ 12 months. The ORR by CPS ≥ 1 and CPS &lt; 1 status was 35.3% and 12.1%, respectively. The ORR by histology was 28.8% for papillary, 9.5% for chromophobe, and 30.8% for unclassified. Overall, the median progression-free survival was 4.2 months (95% CI, 2.9 to 5.6); the 24-month rate was 18.6%. The median overall survival was 28.9 months (95% CI, 24.3 months to not reached); the 24-month rate was 58.4%. Overall, 69.7% of patients reported treatment-related adverse events, most commonly pruritus (20.0%) and hypothyroidism (14.5%). Two deaths were treatment related (pneumonitis and cardiac arrest).</p>
                </sec>
                <sec>
                  <title>CONCLUSION</title>
                  <p>First-line pembrolizumab monotherapy showed promising antitumor activity in nccRCC. The safety profile was similar to that observed in other tumor types.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="subject_thes">
                <compound-kwd>
                  <compound-kwd-part content-type="term">261-492-5651-10662</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">Response duration</compound-kwd-part>
                  <compound-kwd-part content-type="hits">18</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">261-11091-566-9263</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">Monotherapy</compound-kwd-part>
                  <compound-kwd-part content-type="hits">15</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">283-424-3231-2482</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">Clear cell RCC</compound-kwd-part>
                  <compound-kwd-part content-type="hits">13</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">261-492-3532-2370-5109</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">Disease control rate</compound-kwd-part>
                  <compound-kwd-part content-type="hits">12</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">261-492-3532-4809-5347</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">RECIST</compound-kwd-part>
                  <compound-kwd-part content-type="hits">9</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">261-492-3532-9726</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">Antitumor activity</compound-kwd-part>
                  <compound-kwd-part content-type="hits">8</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">3282-3306-2666-6279</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">Programmed death ligand 1</compound-kwd-part>
                  <compound-kwd-part content-type="hits">7</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">261-492-3532-4809-5347</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">RECIST</compound-kwd-part>
                  <compound-kwd-part content-type="hits">3</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">3282-3306-2666-6279</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">Programmed death ligand 1</compound-kwd-part>
                  <compound-kwd-part content-type="hits">2</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">3282-3306-2666-6275</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">Programmed cell death protein 1</compound-kwd-part>
                  <compound-kwd-part content-type="hits">2</compound-kwd-part>
                </compound-kwd>
              </kwd-group>
              <kwd-group kwd-group-type="drug_thes">
                <compound-kwd>
                  <compound-kwd-part content-type="term">242</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">pembrolizumab</compound-kwd-part>
                  <compound-kwd-part content-type="hits">22</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">1597</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">CP</compound-kwd-part>
                  <compound-kwd-part content-type="hits">5</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">137</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">sunitinib malate</compound-kwd-part>
                  <compound-kwd-part content-type="hits">4</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">307</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">everolimus</compound-kwd-part>
                  <compound-kwd-part content-type="hits">4</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">242</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">pembrolizumab</compound-kwd-part>
                  <compound-kwd-part content-type="hits">3</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">242</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">pembrolizumab</compound-kwd-part>
                  <compound-kwd-part content-type="hits">2</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">175</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">prednisone</compound-kwd-part>
                  <compound-kwd-part content-type="hits">2</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">2008</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">sirolimus</compound-kwd-part>
                  <compound-kwd-part content-type="hits">1</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">14</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">nivolumab</compound-kwd-part>
                  <compound-kwd-part content-type="hits">1</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">42</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">interferon α</compound-kwd-part>
                  <compound-kwd-part content-type="hits">1</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">171</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">cabozantinib-s-malate</compound-kwd-part>
                  <compound-kwd-part content-type="hits">1</compound-kwd-part>
                </compound-kwd>
              </kwd-group>
              <kwd-group kwd-group-type="gene_thes">
                <compound-kwd>
                  <compound-kwd-part content-type="term">38092-20072</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">CD274</compound-kwd-part>
                  <compound-kwd-part content-type="hits">13</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">38092-34311</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">TP53INP2</compound-kwd-part>
                  <compound-kwd-part content-type="hits">11</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">38092-29187</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">PDCD1</compound-kwd-part>
                  <compound-kwd-part content-type="hits">7</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">38116-38094-8</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">DCR</compound-kwd-part>
                  <compound-kwd-part content-type="hits">5</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">38092-22496</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">ESPN</compound-kwd-part>
                  <compound-kwd-part content-type="hits">3</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">38092-29187</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">PDCD1</compound-kwd-part>
                  <compound-kwd-part content-type="hits">2</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">38092-20072</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">CD274</compound-kwd-part>
                  <compound-kwd-part content-type="hits">1</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">38092-21186</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">CTLA4</compound-kwd-part>
                  <compound-kwd-part content-type="hits">1</compound-kwd-part>
                </compound-kwd>
              </kwd-group>
              <counts>
                <fig-count count="3"/>
                <table-count count="3"/>
                <equation-count count="0"/>
                <ref-count count="28"/>
                <page-count count="0"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <sec sec-type="introduction">
              <title>INTRODUCTION</title>
              <p>Worldwide, it is estimated that more than 400,000 people will be diagnosed with kidney cancer in 2020.<sup><xref rid="b1" ref-type="bibr">1</xref></sup> Because the most common type of kidney cancer is renal cell carcinoma (RCC) and approximately 70% of patients with RCC have clear cell histology (ccRCC), most approved therapies were developed in the ccRCC population.<sup><xref rid="b2" ref-type="bibr">2</xref></sup> The remaining cases of RCC, broadly defined as non–clear cell renal cell carcinoma (nccRCC), compose a heterogeneous group of tumors that originate from the kidney and lack effective therapies.<sup><xref rid="b3" ref-type="bibr">3</xref></sup> Most clinical trials in patients with nccRCC have been conducted to explore antivascular endothelial growth factor (VEGF) therapies in predominantly papillary RCC populations, and objective response rates (ORR) were low (&lt; 15%).<sup><xref rid="b2" ref-type="bibr">2</xref>,<xref rid="b3" ref-type="bibr">3</xref></sup> The data for mammalian target of rapamycin (mTOR) inhibitors suggest even lower overall efficacy in patients with nccRCC.<sup><xref rid="b3" ref-type="bibr">3</xref></sup> Because of the limited positive clinical trial data for antiangiogenic and mTOR-targeted agents in patients with nccRCC, the National Comprehensive Cancer Network (NCCN) treatment guidelines recommend participation in a clinical trial as a preferred strategy for patients with nccRCC.<sup><xref rid="b2" ref-type="bibr">2</xref></sup></p>
              <boxed-text id="B1" position="anchor" orientation="portrait">
                <sec sec-type="context-box">
                  <title>CONTEXT</title>
                  <p>
                    <list list-type="simple">
                      <list-item>
                        <p>
                          <bold>Key Objective</bold>
                        </p>
                      </list-item>
                      <list-item>
                        <p>To determine if it is possible to treat advanced or metastatic non–clear cell renal cell carcinoma (nccRCC) with pembrolizumab monotherapy in the first-line setting.</p>
                      </list-item>
                      <list-item>
                        <p>
                          <bold>Knowledge Generated</bold>
                        </p>
                      </list-item>
                      <list-item>
                        <p>Pembrolizumab monotherapy demonstrated promising antitumor activity and survival in patients treated in the first-line setting of advanced or metastatic nccRCC. Pembrolizumab monotherapy demonstrated an objective response rate of 26.7% in the overall nccRCC population, which was consistent across key subgroups including International Metastatic RCC Database risk groups, patients with varying histologic subtypes, and patients with tumors with high-programmed death ligand 1 status. The median progression-free survival was 4.2 months, and the median overall survival was 28.9 months.</p>
                      </list-item>
                      <list-item>
                        <p>
                          <bold>Relevance</bold>
                        </p>
                      </list-item>
                      <list-item>
                        <p>Pembrolizumab monotherapy may be a potential treatment option for nccRCC.</p>
                      </list-item>
                    </list>
                  </p>
                </sec>
              </boxed-text>
              <p>Cytokine-based immunotherapies such as interleukin 2 and interferon α were beneficial in only a small group of patients with RCC and showed virtually no activity in patients with nccRCC.<sup><xref rid="b4" ref-type="bibr">4</xref>-<xref rid="b7" ref-type="bibr">7</xref></sup> As understanding of the role of immune evasion in RCC has improved, more recent treatment approaches for patients with advanced RCC have used immune checkpoint inhibitors that target the programmed death 1 (PD-1) and the cytotoxic T-lymphocyte–associated antigen (CTLA-4) pathways. Therefore, it was likely that there was therapeutic potential in inhibiting the PD-1 pathway in patients with nccRCC. The phase II KEYNOTE-427 study (ClinicalTrials.gov identifier: <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT02853344">NCT02853344</ext-link>) was conducted to evaluate the efficacy and safety of the PD-1 inhibitor pembrolizumab as monotherapy for first-line treatment of patients with advanced ccRCC (cohort A) and patients with advanced nccRCC (cohort B). Analysis of cohort A showed that pembrolizumab monotherapy has considerable antitumor activity in previously untreated patients with ccRCC.<sup><xref rid="b8" ref-type="bibr">8</xref></sup> Herein, we present the results of pembrolizumab monotherapy in previously untreated patients with nccRCC (cohort B).</p>
            </sec>
            <sec sec-type="methods">
              <title>METHODS</title>
              <sec>
                <title>Study Design and Objectives</title>
                <p>KEYNOTE-427 (ClinicalTrials.gov identifier: <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT02853344">NCT02853344</ext-link>) was an international, single-arm, open-label, multicohort, multicenter phase II trial performed at 61 sites in 10 countries. Patients enrolled in the study were administered intravenous pembrolizumab 200 mg once every 3 weeks until disease progression, unacceptable toxicity, or a total treatment duration of 24 months (maximum of 35 doses). The primary objective was to estimate ORR per RECIST, version 1.1 (RECIST v1.1) as assessed by blinded independent central review (BICR) in patients with nccRCC.</p>
                <p>The Protocol and its amendments were approved by the appropriate institutional review board or independent ethics committee at each site. The trial was conducted per Good Clinical Practice guidelines and the Declaration of Helsinki. All patients provided written informed consent.</p>
              </sec>
              <sec sec-type="subjects">
                <title>Patient Characteristics</title>
                <p>Eligible patients were ≥ 18 years with newly diagnosed or recurrent stage IV nccRCC as determined by the investigator and measurable disease per RECIST v1.1. Diagnosis of nccRCC was retrospectively confirmed by central pathology review. Subtype histology of nccRCC was determined by central pathology review. Patients must not have received prior systemic therapy for metastatic disease and must have maintained a Karnofsky performance status score ≥ 70 within 10 days before initiating treatment. Prior neoadjuvant and/or adjuvant therapy for RCC was allowed if it was completed more than 12 months before allocation and if it did not include a PD-1 pathway blocker. Exclusion criteria are provided in the Data Supplement (online only).</p>
              </sec>
              <sec>
                <title>Study Assessments</title>
                <p>The primary end point was ORR, per RECIST v1.1 as assessed by BICR. Secondary end points were duration of response (DOR), disease control rate (DCR; defined as the sum of complete responders, partial responders, and patients with stable disease lasting ≥ 6 months), progression-free survival (PFS; defined as the time from first day of study treatment to first documented disease progression per RECIST v1.1 or death, whichever occurred first), overall survival (OS; defined as the time from first day of study treatment to time of death) per RECIST v1.1 by BICR, and safety and tolerability. Exploratory end points were ORR, DOR, and DCR in relation to (1) histology, (2) International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk status, (3) programmed death ligand 1 (PD-L1) combined positive score (CPS), and (4) sarcomatoid differentiation.</p>
                <p>Tumor imaging was performed using computed tomography or magnetic resonance imaging of the chest, abdomen, or pelvis. Imaging assessments were performed at week 12, then every 6 weeks until week 54, and every 12 weeks thereafter. Baseline bone imaging was necessary for confirmation of complete response (CR) and was performed at screening and at weeks 18, 30, 42, and 54, and then every 24 weeks thereafter. Response was assessed according to RECIST v1.1 based on BICR.</p>
                <p>Assessment of PD-L1 expression and sarcomatoid differentiation is described in the Data Supplement.</p>
                <p>Safety was monitored throughout the study and for 30 days after the last dose of pembrolizumab and graded per the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4. Any adverse events (AEs) associated with pembrolizumab exposure with immunologic etiology were recorded as immune-mediated AEs. Patients were monitored for any serious AEs and immune-mediated AEs for up to 90 days after study completion.</p>
              </sec>
              <sec>
                <title>Statistical Analyses</title>
                <p>ORR was calculated as the proportion of patients in the analysis population who experienced CR or partial response (PR). The 95% CIs were calculated using the Clopper-Pearson method based on binomial distribution. The Kaplan-Meier method for censored data was used to estimate OS, PFS, and DOR from the date of the first exposure to pembrolizumab to the database cutoff date. The DOR analysis population included all responders. No statistical adjustments were performed for multiple comparisons.</p>
              </sec>
            </sec>
            <sec sec-type="results">
              <title>RESULTS</title>
              <sec sec-type="subjects">
                <title>Patients</title>
                <p>In total, 165 patients were enrolled across nine countries in cohort B. The median time from enrollment to database cutoff was 31.5 months (range, 22.7-38.8). The median age was 62 years (range, 22-86), and 66.1% of patients were male (Table <xref rid="tbl1" ref-type="table">1</xref>). The median duration of therapy was 6.9 months (range, 0.03-29.2). The PD-L1 expression status was CPS ≥ 1 in 61.8% (n = 102) of patients. Fifty-three patients (32.1%) and 112 patients (67.9%) were classified into favorable and intermediate or poor IMDC risk categories, respectively.</p>
                <table-wrap id="tbl1" orientation="portrait" position="float">
                  <label>TABLE 1.</label>
                  <caption>
                    <p>Patient Demographics and Characteristics at Baseline</p>
                  </caption>
                  <graphic xlink:href="jco-39-1029-g001"/>
                </table-wrap>
                <p>At data cutoff on February 24, 2020, treatment was ongoing in two patients (1.2%), had been discontinued in 139 patients (84.2%), and was completed in 24 patients (14.5%). Most patients (66.1%) discontinued treatment because of progressive disease (57.0%) or clinical progression (9.1%). Treatment was discontinued because of an AE in 25 patients (15.2%); 16 patients (9.7%) discontinued treatment because of a treatment-related AE (Data Supplement Figure S1, online only). Other reasons for discontinuation were patient withdrawal (n = 3) and treatment with other anticancer therapy (n = 1).</p>
              </sec>
              <sec>
                <title>Efficacy Outcomes in the Total Population</title>
                <p>The ORR was 26.7% (95% CI, 20.1 to 34.1) in the total population: 11 patients (6.7%) achieved CR and 33 patients (20.0%) achieved PR; the DCR was 43.0% (Table <xref rid="tbl2" ref-type="table">2</xref>). Ninety-one patients (55.2%) had a reduction in target lesions; 20 patients (12.1%) had reductions ≥ 80%, and seven patients (4.2%) had 100% target lesion reduction (Fig <xref ref-type="fig" rid="fig1">1</xref>A).</p>
                <table-wrap id="tbl2" orientation="portrait" position="float">
                  <label>TABLE 2.</label>
                  <caption>
                    <p>Response Rate in the Overall Population and in Patient Subgroups Per RECIST v1.1 by BICR</p>
                  </caption>
                  <graphic xlink:href="jco-39-1029-g002"/>
                </table-wrap>
                <fig id="fig1" fig-type="figure" orientation="portrait" position="float">
                  <label>FIG 1.</label>
                  <caption>
                    <p>Maximum change from baseline in target lesions (A),<sup>a</sup> time to response and response duration (B), and Kaplan-Meier estimate of DOR (C) based on blinded independent central review. <sup>a</sup>Maximum change from baseline in target lesions by central review was assessed for patients who received ≥ 1 dose of pembrolizumab, had baseline imaging with measurable disease per RECIST v1.1, and had a postbaseline assessment (n = 155). +, ongoing response; CR, complete response; DOR, duration of response; PD, progressive disease; PR, partial response.</p>
                  </caption>
                  <graphic xlink:href="jco-39-1029-g003"/>
                </fig>
                <p>The median time to response was 2.8 months (range, 0.1-8.3), and the median DOR was 29.0 months (range, 2.8-31.6 +). By Kaplan-Meier estimate, the percentage of responders with response durations ≥ 12 months and ≥ 18 months was 59.7% and 57.0%, respectively (Fig <xref ref-type="fig" rid="fig1">1</xref>B). Of the 44 patients who experienced a CR or PR, 19 had an ongoing response at data cutoff (Fig <xref ref-type="fig" rid="fig1">1</xref>B) and 20 had experienced subsequent progressive disease per BICR (Fig <xref ref-type="fig" rid="fig1">1</xref>C). For the other five responders, two discontinued treatment because of an AE (acute coronary syndrome and hemorrhagic stroke), two because of radiographic progression, and one because of clinical progression.</p>
                <p>The median PFS for the entire nccRCC group was 4.2 months (95% CI, 2.9 to 5.6) (Fig <xref ref-type="fig" rid="fig2">2</xref>A); 12- and 24-month PFS rates were 24.7% and 18.6%, respectively. The 12- and 24-month OS rates were 73.2% and 58.4%, respectively; the median OS was 28.9 months (95% CI, 24.3 months to not reached; Fig <xref ref-type="fig" rid="fig2">2</xref>B).</p>
                <fig id="fig2" fig-type="figure" orientation="portrait" position="float">
                  <label>FIG 2.</label>
                  <caption>
                    <p>Kaplan-Meier curves for (A) progression-free survival and (B) overall survival. NR, not reached; OS, overall survival; PFS, progression-free survival.</p>
                  </caption>
                  <graphic xlink:href="jco-39-1029-g004"/>
                </fig>
              </sec>
              <sec>
                <title>Efficacy Outcomes by PD-L1 Expression</title>
                <p>For patients with CPS ≥ 1 (n = 102), the confirmed ORR was 35.3% (95% CI, 26.1 to 45.4) (Fig <xref ref-type="fig" rid="fig3">3</xref>; Table <xref rid="tbl2" ref-type="table">2</xref>). The DCR was 50.0% (95% CI, 39.9 to 60.1). The median DOR was 29.0 months (range, 2.8 + to 31.6 +), the median PFS was 5.6 months (95% CI, 2.9 to 8.3), and the median OS was 30.0 months (95% CI, 22.9 to not reached) (Data Supplement Table S1, online only). For patients with CPS &lt; 1 (n = 58), the confirmed ORR was 12.1% (95% CI, 5.0 to 23.3) (Fig <xref ref-type="fig" rid="fig3">3</xref>; Table <xref rid="tbl2" ref-type="table">2</xref>). The DCR was 31.0% (95% CI, 19.5 to 44.5). The median DOR was 9.5 months (range, 2.8 to 26.0 +), the median PFS was 3.7 months (95% CI, 2.8 to 4.2), and the median OS was 26.6 months (95% CI, 19.2 months to not reached) (Data Supplement Table S1).</p>
                <fig id="fig3" fig-type="figure" orientation="portrait" position="float">
                  <label>FIG 3.</label>
                  <caption>
                    <p>ORR by patient subgroup. <sup>a</sup>Five patients had missing PD-L1 status. CPS, combined positive score; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; ORR, objective response rate; PD-L1, programmed death ligand 1; RCC, renal cell carcinoma.</p>
                  </caption>
                  <graphic xlink:href="jco-39-1029-g005"/>
                </fig>
              </sec>
              <sec>
                <title>Efficacy Outcomes by Histology</title>
                <p>The confirmed ORRs for patients with papillary, chromophobe, and unclassified histology were 28.8% (95% CI, 20.8% to 37.9%), 9.5% (95% CI, 1.2% to 30.4%), and 30.8% (95% CI, 14.3% to 51.8%), respectively (Fig <xref ref-type="fig" rid="fig3">3</xref>;Table <xref rid="tbl2" ref-type="table">2</xref>). The median DOR ranged from 29.0 months to not reached (Data Supplement Table S1). For patients with papillary histology, the DCR was 47.5% (95% CI, 38.2% to 56.9%), the median PFS was 5.5 months (95% CI, 3.9 to 6.9), and the median OS was 31.5 (95% CI, 25.5 to not reached) (Table <xref rid="tbl2" ref-type="table">2</xref>; Data Supplement Table S1). For patients with chromophobe histology, the DCR was 33.3% (95% CI, 14.6% to 57.0%), the median PFS was 3.9 months (95% CI, 2.6 to 6.9), and the median OS was 23.5 months (95% CI, 9.3 to not reached) (Table <xref rid="tbl2" ref-type="table">2</xref>, Data Supplement Table S1). For patients with unclassified histology, the DCR was 30.8% (95% CI, 14.3% to 51.8), the median PFS was 2.8 months (95% CI, 2.8 to 5.1), and the median OS was 17.6 months (95% CI, 7.5 to not reached) (Data Supplement Table S1).</p>
              </sec>
              <sec>
                <title>Efficacy by Sarcomatoid Differentiation</title>
                <p>Among patients with sarcomatoid differentiation (n = 38), the confirmed ORR was 42.1% (95% CI, 26.3% to 59.2%) (Fig <xref ref-type="fig" rid="fig3">3</xref>; Table <xref rid="tbl2" ref-type="table">2</xref>). The DCR was 55.3% (95% CI, 38.3% to 71.4%) (Table <xref rid="tbl2" ref-type="table">2</xref>). The median DOR was 15.3 months (range, 2.8 + to 29.5 +), the median PFS was 6.9 months (95% CI, 2.8 to 15.4), and the median OS was 25.5 months (95% CI, 13.1 to 30.0) (Data Supplement Table S1).</p>
              </sec>
              <sec>
                <title>Efficacy Outcomes by IMDC Risk Category</title>
                <p>For patients with favorable IMDC risk (n = 53), the confirmed ORR was 32.1% (95% CI, 19.9% to 46.3%) (Fig <xref ref-type="fig" rid="fig3">3</xref>; Table <xref rid="tbl2" ref-type="table">2</xref>). The DCR was 43.4% (95% CI, 29.8% to 57.7%). The median DOR was 11.0 months (range, 2.8 to 27.7 +), the median PFS was 5.3 months (95% CI, 2.9 to 8.2), and the median OS was not reached (95% CI, 30.4 to not reached) (Data Supplement Table S1).</p>
                <p>In the intermediate or poor IMDC risk subgroup (n = 112), the confirmed ORR was 24.1% (95% CI, 16.5% to 33.1%) (Fig <xref ref-type="fig" rid="fig3">3</xref>; Table <xref rid="tbl2" ref-type="table">2</xref>). The DCR was 42.9% (95% CI, 33.5% to 52.6%). The median DOR was 29.0 months (range, 2.8 to 31.6 +), the median PFS was 4.0 months (95% CI, 2.8 to 6.2), and the median OS was 24.5 months (95% CI, 16.7 to 30.0) (Data Supplement Table S1).</p>
              </sec>
              <sec>
                <title>Safety</title>
                <p>A total of 69.7% of patients experienced treatment-related AEs of any grade; 17% experienced treatment-related AEs of grade 3-5 (Table <xref rid="tbl3" ref-type="table">3</xref>). The most commonly reported treatment-related AEs of any grade were pruritus (20.0%), hypothyroidism (14.5%), fatigue (13.9%), and diarrhea (13.9%). Colitis (1.8%) and fatigue (1.8%) was the most commonly reported grade 3-5 treatment-related AE. Discontinuation because of a treatment-related AE was reported for 16 patients (9.7%) (Data Supplement Table S2, online only). Eight patients died of AEs, two of which were considered related to treatment (pneumonia and cardiac arrest); six deaths (pneumonia, ischemic stroke, respiratory failure, bleeding from esophageal varices left ventricular failure, and multiple organ dysfunction syndrome) were not considered related to treatment. Immune-mediated AEs were reported in 32.7% of patients (grade 1 or 2, 40 of 54 patients) (Table <xref rid="tbl3" ref-type="table">3</xref>). The most commonly reported immune-mediated AEs were hypothyroidism (15.8%), hyperthyroidism (6.7%), colitis (2.4%), and hepatitis (2.4%). Hepatitis (2.4%) was the most commonly reported grade 3-5 immune-mediated AE.</p>
                <table-wrap id="tbl3" orientation="portrait" position="float">
                  <label>TABLE 3.</label>
                  <caption>
                    <p>Treatment-Related and Immune-Mediated AEs</p>
                  </caption>
                  <graphic xlink:href="jco-39-1029-g006"/>
                </table-wrap>
                <p>Systemic corticosteroids were used for the management of 71 immune-related AE episodes. Eighteen episodes (25.4%) were managed with a high starting dose of corticosteroids (≥ 40 mg/d prednisone or equivalent), and four (5.6%) were managed with a low starting dose of corticosteroids (&lt; 40 mg/d prednisone or equivalent). The remaining 49 episodes (69.0%) did not necessitate treatment with corticosteroids.</p>
              </sec>
            </sec>
            <sec sec-type="discussion">
              <title>DISCUSSION</title>
              <p>The single-arm, phase II KEYNOTE-427 study is the first and largest interventional clinical study conducted in a cohort of patients with previously untreated advanced nccRCC. First-line pembrolizumab monotherapy showed promising antitumor activity (ORR = 26.7%) in the overall nccRCC population, consistent results across IMDC risk groups, and promising activity in selected patient subgroups with tumors with high PD-L1 expression, papillary or unclassified histology, and sarcomatoid differentiation. The median DOR was 29.0 months, with most patients achieving a response for ≥ 12 months. The median PFS was 4.2 months, the median OS was 28.9 months, and the 24-month OS rate was 58.4%. These findings are consistent with those of other studies of PD-1/PD-L1 inhibitors, both as monotherapy and in combination treatment.<sup><xref rid="b9" ref-type="bibr">9</xref>-<xref rid="b12" ref-type="bibr">12</xref></sup></p>
              <p>The results of the current study show that pembrolizumab monotherapy provides durable antitumor activity in untreated patients with nccRCC. Furthermore, the confirmation of an nccRCC diagnosis by central pathology in KEYNOTE-427 provides confidence in our results, given the histologic diversity of these cancers.</p>
              <p>Because the focus of RCC clinical trials of targeted systemic therapies has predominantly been on patients with ccRCC, the NCCN kidney cancer guidelines indicate that enrollment in clinical trials is the preferred strategy for patients with nccRCC.<sup><xref rid="b2" ref-type="bibr">2</xref></sup> Current standard-of-care systemic treatment options recommended by NCCN guidelines for patients with nccRCC include sunitinib, everolimus, and cabozantinib.<sup><xref rid="b2" ref-type="bibr">2</xref></sup> The phase II ASPEN and ESPN trials were conducted to assess efficacy and safety of sunitinib versus everolimus in patients with nccRCC, and recommendations were primarily based on the results of the primary end point of PFS.<sup><xref rid="b13" ref-type="bibr">13</xref>,<xref rid="b14" ref-type="bibr">14</xref></sup> Notably, nccRCC histology in ASPEN and ESPN was not confirmed by central pathology review. Tumor response was evaluated as a secondary end point in both trials. In the ASPEN trial, the ORR was 18% (PR, n = 9) in the sunitinib arm and 9% (CR, n = 2; PR, n = 4) in the everolimus arm.<sup><xref rid="b13" ref-type="bibr">13</xref></sup> In the ESPN trial, the ORR was 9% (PR, n = 3) with first-line sunitinib and 3% (PR, n = 1) with first-line everolimus.<sup><xref rid="b14" ref-type="bibr">14</xref></sup> Despite guideline recommendations for these regimens, the results of these approaches demonstrate that more effective treatment options for nccRCC are needed.</p>
              <p>The safety profile of pembrolizumab monotherapy in this study is generally consistent with what has been observed in other tumor types.<sup><xref rid="b15" ref-type="bibr">15</xref></sup> Overall, 69.7% of patients reported treatment-related AEs of any grade and 17% reported treatment-related AEs of grade 3-5. The most reported immune-mediated AEs were hypothyroidism, hyperthyroidism, colitis, and hepatitis, consistent with a recent systematic review and meta-analysis of PD-1/PD-L1 inhibitors.<sup><xref rid="b16" ref-type="bibr">16</xref></sup> Two of the eight deaths that occurred in the study were considered related to treatment (pneumonitis and cardiac arrest). Although rare, serious and potentially fatal cases of pneumonitis and cardiotoxicity can occur with the use of immune checkpoint inhibitors such as pembrolizumab.<sup><xref rid="b17" ref-type="bibr">17</xref>,<xref rid="b18" ref-type="bibr">18</xref></sup></p>
              <p>The antitumor activity of pembrolizumab monotherapy was also demonstrated across key patient subgroups. ORR in the overall nccRCC population was similar to ORRs in the favorable and intermediate or poor IMDC risk groups, suggesting that antitumor activity was generally consistent across IMDC risk categories. When evaluated by RCC histology, ORRs were higher for patients with papillary and unclassified RCC than for patients with chromophobe RCC. This result is similar to that reported in a retrospective analysis of nivolumab in nccRCC, in which the highest response rate was observed in patients with unclassified histology, followed by papillary and chromophobe RCC.<sup><xref rid="b10" ref-type="bibr">10</xref></sup> Although there were few patients in this study with chromophobe RCC (n = 21) to draw meaningful conclusions, it is unclear why these patients seem to have a poorer response with anti-PD-1 therapies because this histologic subtype is traditionally associated with better survival than other RCC subtypes.<sup><xref rid="b19" ref-type="bibr">19</xref></sup> Given the rarity of chromophobe histology, the majority of studies are retrospective with substantial heterogeneity; therefore, there is no consensus on the optimal therapy for patients with chromophobe histology.<sup><xref rid="b20" ref-type="bibr">20</xref></sup> The effectiveness of pembrolizumab might also be influenced by PD-L1 status. Despite differing methodologies (eg, choice of antibody) and positivity thresholds (eg, ≥ 5% positivity), PD-L1 expression has been reported in 11%-20% of samples from patients with nccRCC.<sup><xref rid="b21" ref-type="bibr">21</xref>-<xref rid="b25" ref-type="bibr">25</xref></sup> Following the same methodology as used in this study, PD-L1 expression, defined as CPS ≥ 1, in the KEYNOTE-426 and KEYNOTE-427 cohort A studies was reported in 47% and 60% of patients with ccRCC, respectively.<sup><xref rid="b8" ref-type="bibr">8</xref>,<xref rid="b26" ref-type="bibr">26</xref></sup> Although responses in this study were observed in patients with CPS ≥ 1 and those with CPS &lt; 1, the ORR was three times higher in patients with CPS ≥ 1 (35.3%) than in those with CPS &lt; 1 (12.1%). The results of this study also showed relatively high response rates in patients with sarcomatoid differentiation (ORR, 42.1%). Recently reported results of ongoing studies suggest that sarcomatoid differentiation and DNA and RNA analyses of the tumor microenvironment may play a role in predicting response to PD-1 or PD-L1 inhibitors.<sup><xref rid="b11" ref-type="bibr">11</xref>,<xref rid="b27" ref-type="bibr">27</xref>,<xref rid="b28" ref-type="bibr">28</xref></sup> Data from the current study suggest that sarcomatoid differentiation may be a histologic biomarker for response to checkpoint inhibitor therapy in patients with nccRCC, as was observed in patients with ccRCC.</p>
              <p>The current study has several limitations. First, the single-arm study design limits comparisons of response rate and survival outcomes with currently recommended regimens. Second, the heterogeneity of the nccRCC patient population makes subgroup analyses difficult to identify which patients achieve the greatest benefit. Furthermore, despite central pathology review, we were unable to subgroup patients into papillary type I and type II.</p>
              <p>In conclusion, pembrolizumab monotherapy showed promising antitumor activity and survival for patients with nccRCC. The safety and tolerability of pembrolizumab monotherapy are consistent with those reported in previous studies. Given the lack of established therapy for nccRCC and favorable ORR relative to VEGF and mTOR therapies, pembrolizumab monotherapy may be a potential treatment option for nccRCC. Additional studies to evaluate antitumor activity of immune checkpoint blockade coupled with studies to validate tissue-based biomarkers of response will better elucidate the role of pembrolizumab treatment in nccRCC.</p>
            </sec>
          </body>
          <back>
            <fn-group content-type="presented-at">
              <title>PRIOR PRESENTATION</title>
              <fn specific-use="presented-at" fn-type="presented-at">
                <p>Presented in part at the ASCO20 Virtual Meeting, May 29-31, 2020; presented at the 2019 ASCO Genitourinary Cancers Symposium, San Francisco, CA, February 14-16, 2019; presented at the 2019 ASCO Annual Meeting, Chicago, IL, May 31-June 4, 2019; presented at the 2019 ESMO Annual Meeting, Barcelona, Spain, September 27-October 1, 2019.</p>
              </fn>
            </fn-group>
            <fn-group content-type="supported-by">
              <title>SUPPORT</title>
              <fn specific-use="supported-by" fn-type="supported-by">
                <p>Supported by Merck Sharp &amp; Dohme Corp, a subsidiary of Merck &amp; Co, Inc, Kenilworth, NJ. This work was also supported by a grant from the National Cancer Institute, USA Kidney SPORE (5P50CA101942).</p>
              </fn>
            </fn-group>
            <fn-group content-type="trial">
              <title>CLINICAL TRIAL INFORMATION</title>
              <fn specific-use="other" fn-type="other">
                <p>
                  <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT02853344">NCT02853344</ext-link>
                </p>
              </fn>
            </fn-group>
            <ack>
              <title>ACKNOWLEDGMENT</title>
              <p>The authors thank the patients and their families and all investigators and site personnel. The authors also thank Scot Ebbinghaus, Karla Rodriguez-Lopez, Trevor Newhook, Jialin Xu, Sabrina Wan, Susmita Gupta, Kate Fogarty, Yuying Hwang and Xiaoqi Du (employees of Merck Sharp &amp; Dohme Corp, a subsidiary of Merck &amp; Co, Inc, Kenilworth, NJ), and Sabina Signoretti (Brigham and Women's Hospital, Boston, MA) for their contributions to the study. Medical writing and/or editorial assistance was provided by Robert Steger, PhD, and Matthew Grzywacz, PhD, of ApotheCom (Yardley, PA). This assistance was funded by Merck Sharp &amp; Dohme Corp, a subsidiary of Merck &amp; Co, Inc, Kenilworth, NJ.</p>
            </ack>
            <sec id="s16" sec-type="data-availability">
              <title>DATA SHARING STATEMENT</title>
              <p>The data sharing policy for Merck Sharp &amp; Dohme Corp, a subsidiary of Merck &amp; Co, Inc, Kenilworth, NJ, including restrictions, is available at <ext-link ext-link-type="uri" xlink:href="http://engagezone.msd.com/ds_documentation.php">http://engagezone.msd.com/ds_documentation.php</ext-link>. Requests for access to the clinical study data can be submitted through the Engagezone site or via email to <email>dataaccess@merck.com</email>.</p>
            </sec>
            <sec sec-type="contributed">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p><bold>Conception and design:</bold> David F. McDermott, Rodolfo F. Perini, Charles Schloss, Michael B. Atkins</p>
              <p><bold>Provision of study materials or patients:</bold> Georg A. Bjarnason, Daniel Castellano, Michael B. Atkins</p>
              <p><bold>Collection and assembly of data:</bold> Jae-Lyun Lee, Marek Ziobro, Cristina Suarez, Przemyslaw Langiewicz, Vsevolod Borisovich Matveev, Pawel Wiechno, Rustem Airatovich Gafanov, Piotr Tomczak, Frederic Pouliot, Frede Donskov, Boris Yakovlevich Alekseev, Sang Joon Shin, Georg A. Bjarnason, Charles Schloss</p>
              <p><bold>Data analysis and interpretation:</bold> Jae-Lyun Lee, Marek Ziobro, Przemyslaw Langiewicz, Pawel Wiechno, Rustem Airatovich Gafanov, Frederic Pouliot, Frede Donskov, Boris Yakovlevich Alekseev, Sang Joon Shin, Georg A. Bjarnason, Daniel Castellano, Rachel Kloss Silverman, Rodolfo F. Perini, Charles Schloss, Michael B. Atkins</p>
              <p><bold>Manuscript writing:</bold> All authors</p>
              <p><bold>Final approval of manuscript:</bold> All authors</p>
              <p><bold>Accountable for all aspects of the work:</bold> All authors</p>
            </sec>
            <sec sec-type="disclosures">
              <title>AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST</title>
              <sec>
                <title>Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma</title>
                <p>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to <ext-link ext-link-type="uri" xlink:href="http://www.asco.org/rwc">www.asco.org/rwc</ext-link> or <ext-link ext-link-type="uri" xlink:href="http://ascopubs.org/jco/authors/author-center">ascopubs.org/jco/authors/author-center</ext-link>.</p>
                <p>Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (<ext-link ext-link-type="uri" xlink:href="https://openpaymentsdata.cms.gov/">Open Payments</ext-link>).</p>
              </sec>
              <sec>
                <title>David F. McDermott</title>
                <p><bold>Consulting or Advisory Role:</bold> Bristol-Myers Squibb, Merck, Genentech/Roche, Pfizer, Exelixis, Novartis, Array BioPharma, Peloton Therapeutics, EMD Serono, Jounce Therapeutics, Alkermes, Lilly, Eisai, Calithera Biosciences, Iovance Biotherapeutics</p>
                <p><bold>Research Funding:</bold> Prometheus, Bristol-Myers Squibb, Merck, Genentech, Novartis, Alkermes, Peloton Therapeutics</p>
                <p><bold>Other Relationship:</bold> Beth Israel Deaconess Medical Center</p>
                <p><bold>(OPTIONAL) Uncompensated Relationships:</bold> X4 Pharmaceuticals, AVEO</p>
              </sec>
              <sec>
                <title>Jae-Lyun Lee</title>
                <p><bold>Stock and Other Ownership Interests:</bold> Myovant Sciences</p>
                <p><bold>Honoraria:</bold> Bristol-Myers Squibb, Astellas Pharma, Pfizer, AstraZeneca, MSD</p>
                <p><bold>Consulting or Advisory Role:</bold> Pfizer, Sanofi/Aventis, Bristol-Myers Squibb, Alteogen, GI Innovation, MSD, Merck, AstraZeneca</p>
                <p><bold>Research Funding:</bold> Pfizer, Janssen, Novartis, Bristol-Myers Squibb, Roche/Genentech, AstraZeneca/MedImmune, MSD, Bayer Schering Pharma, Seattle Genetics</p>
              </sec>
              <sec>
                <title>Marek Ziobro</title>
                <p><bold>Consulting or Advisory Role:</bold> Bristol-Myers Squibb, MSD, Pierre Fabre, Pierre Fabre, Ipsen</p>
                <p><bold>Speakers' Bureau:</bold> Bristol-Myers Squibb, MSD, Novartis, Roche</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Bristol-Myers Squibb, Roche, Novartis, Pierre Fabre</p>
              </sec>
              <sec>
                <title>Cristina Suarez</title>
                <p><bold>Consulting or Advisory Role:</bold> Bristol-Myers Squibb, Ipsen, Sanofi, Pfizer, EUSA Pharma, Astellas Pharma, Novartis, Merck Sharp &amp; Dohme</p>
                <p><bold>Speakers' Bureau:</bold> Bristol-Myers Squibb, Ipsen, PfizerRoche/Genentech, AstraZeneca, Merck Sharp &amp; Dohme</p>
                <p><bold>Research Funding (Institution):</bold> Astellas Pharma, Roche/Genentech, Exelixis, AstraZeneca, Bristol-Myers Squibb, Pfizer, Novartis, Janssen Oncology, Calithera Biosciences, AB Science, Arog, AVEO, Bayer, SFJ Pharmaceuticals Group, Blueprint Medicines, Clovis Oncology, Boehringer Ingelheim, Cougar Biotechnology, Deciphera, GlaxoSmithKline, Incyte, Karyopharm Therapeutics, MedImmune, Nanobiotix, Millennium, Puma Biotechnology, Teva</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Bristol-Myers Squibb, Roche, Ipsen</p>
              </sec>
              <sec>
                <title>Vsevolod Borisovich Matveev</title>
                <p><bold>Honoraria:</bold> Ipsen, Bayer, Bristol-Myers Squibb, AstraZeneca, Janssen, Astellas Pharma, MSD</p>
                <p><bold>Expert Testimony:</bold> Bristol-Myers Squibb, Bayer, MSD</p>
              </sec>
              <sec>
                <title>Pawel Wiechno</title>
                <p><bold>Honoraria:</bold> Pfizer, Astellas Pharma, Bristol-Myers Squibb, Bayer, Janssen-Cilag, Merck</p>
                <p><bold>Consulting or Advisory Role:</bold> Merck, Pfizer, Bayer, Bristol-Myers Squibb, Astellas Pharma, Janssen-Cilag</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Pfizer, Astllas</p>
              </sec>
              <sec>
                <title>Rustem Airatovich Gafanov</title>
                <p><bold>Honoraria:</bold> Janssen, Astellas Pharma, Bayer, Sanofi, MSD, Bristol-Myers Squibb, Pfizer</p>
                <p><bold>Consulting or Advisory Role:</bold> Janssen, Astellas Pharma, Bayer, Sanofi, MSD, Bristol-Myers Squibb, Pfizer</p>
                <p><bold>Speakers' Bureau:</bold> Janssen, Astellas Pharma, Bayer, Sanofi, MSD, Bristol-Myers Squibb, Pfizer</p>
              </sec>
              <sec>
                <title>Frederic Pouliot</title>
                <p><bold>Stock and Other Ownership Interests:</bold> Allogene Therapeutics</p>
                <p><bold>Honoraria:</bold> Amgen, Astellas Pharma, Janssen, Bayer, Genzyme, Sanofi, Abbvie, Ferring</p>
                <p><bold>Consulting or Advisory Role:</bold> Amgen, Pfizer, Sanofi, Astellas Pharma, Progenics, Bayer, Janssen, Genzyme</p>
                <p><bold>Speakers' Bureau:</bold> Astellas Pharma, Bayer, Amgen, Sanofi, Janssen</p>
                <p><bold>Research Funding:</bold> Sanofi, Astellas Pharma, Tersera, Janssen, Bayer</p>
                <p><bold>Patents, Royalties, Other Intellectual Property:</bold> Transcriptional system and uses therof for single cell detection</p>
                <p><bold>Other Relationship:</bold> Merck, Progenics</p>
              </sec>
              <sec>
                <title>Frede Donskov</title>
                <p><bold>Research Funding:</bold> Pfizer, Ipsen, MSD Oncology</p>
              </sec>
              <sec>
                <title>Boris Yakovlevich Alekseev</title>
                <p><bold>Honoraria:</bold> Asrtrazeneca, Astellas Pharma, Ferring, Eisai, Janssen, Bayer, MSD, Merck, Pfizer, Roche, Sanofi, Bristol-Myers Squibb</p>
                <p><bold>Consulting or Advisory Role:</bold> AstraZeneca, Astellas Pharma, Bayer, Bristol-Myers Squibb, Ferring, Janssen, Merck, Sanofi, Pfizer, MSD, Roche, Eisai</p>
                <p><bold>Speakers' Bureau:</bold> Janssen, Sanofi, Ferring, Astellas Pharma, Pfizer, AstraZeneca, Bayer, Merck, Bristol-Myers Squibb, MSD, Eisai, Roche</p>
                <p><bold>Research Funding:</bold> AstraZeneca, Merck, Sanofi, Bayer, Astellas Pharma, Janssen, Bristol-Myers Squibb, Bavarian Nordic, Pfizer, ICON Clinical Research, Eisai, MSD, Roche</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> AstraZeneca, Astellas Pharma, Bayer, Bristol-Myers Squibb, Janssen, MSD, Pfizer, Sanofi</p>
              </sec>
              <sec>
                <title>Georg A. Bjarnason</title>
                <p><bold>Stock and Other Ownership Interests:</bold> Merck</p>
                <p><bold>Honoraria:</bold> Pfizer, Novartis, Bristol-Myers Squibb, Eisai, Ipsen</p>
                <p><bold>Consulting or Advisory Role:</bold> Pfizer, Novartis, Bristol-Myers Squibb, Eisai, Ipsen</p>
                <p><bold>Research Funding:</bold> Pfizer, Merck</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Pfizer, Novartis</p>
              </sec>
              <sec>
                <title>Daniel Castellano</title>
                <p><bold>Consulting or Advisory Role:</bold> Janssen Oncology, Roche/Genentech, Astellas Pharma, AstraZeneca, Pfizer, Novartis, Ipsen, Bristol-Myers Squibb, MSD Oncology, Bayer, Lilly, Sanofi, Pierre Fabre, Boehringer Ingelheim</p>
                <p><bold>Research Funding:</bold> Janssen Oncology</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Pfizer, Roche, Bristol-Myers Squibb, AstraZeneca</p>
              </sec>
              <sec>
                <title>Rachel Kloss Silverman</title>
                <p><bold>Employment:</bold> Merck</p>
                <p><bold>Stock and Other Ownership Interests:</bold> Merck</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Merck</p>
              </sec>
              <sec>
                <title>Rodolfo F. Perini</title>
                <p><bold>Employment:</bold> Merck</p>
                <p><bold>Stock and Other Ownership Interests:</bold> Merck</p>
              </sec>
              <sec>
                <title>Charles Schloss</title>
                <p><bold>Employment:</bold> Merck</p>
                <p><bold>Stock and Other Ownership Interests:</bold> Merck</p>
              </sec>
              <sec>
                <title>Michael B. Atkins</title>
                <p><bold>Stock and Other Ownership Interests:</bold> Werewolf Pharma, Pyxis</p>
                <p><bold>Consulting or Advisory Role:</bold> Genentech, Novartis, Bristol-Myers Squibb, Merck, Exelixis, Eisai, Agenus, Arrowhead Pharmaceuticals, Werewolf Pharma, Surface Oncology, Iovance Biotherapeutics, Immunocore, Pyxis, Pneuma Respiratory, Leads Biolabs, Fathom Biotechnology, Aveo, Cota Healthcare, Neoleukin Therapeutics, Adagene, Idera, Ellipses Pharma, AstraZeneca, PACT Pharma, Third Rock Ventures</p>
                <p><bold>Research Funding:</bold> Bristol-Myers Squibb</p>
                <p>No other potential conflicts of interest were reported.</p>
              </sec>
            </sec>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="b1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Xia</surname><given-names>Q</given-names></name>, <etal>et al</etal></person-group>: <article-title>Trends and projections of kidney cancer incidence at the global and national levels, 1990-2030: A Bayesian age-period-cohort modeling study</article-title>. Biomark Res <volume>8</volume>:<fpage>16</fpage>, <year>2020</year></mixed-citation>
              </ref>
              <ref id="b2">
                <label>2.</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><collab>National Comprehensive Cancer Network</collab></person-group>: NCCN Clinical Practice Guidelines in Oncology-Kidney Cancer. V.1.2021, <publisher-name>National Comprehensive Cancer Network</publisher-name>, <year>2020</year>. <ext-link ext-link-type="uri" xlink:href="https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf">https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf</ext-link></mixed-citation>
              </ref>
              <ref id="b3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Maia</surname><given-names>MC</given-names></name>, <etal>et al</etal></person-group>: <article-title>Systemic therapy for non-clear cell renal cell carcinoma</article-title>. Am Soc Clin Oncol Educ Book <volume>37</volume>:<fpage>337</fpage>-<lpage>342</lpage>, <year>2017</year></mixed-citation>
              </ref>
              <ref id="b4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Bacik</surname><given-names>J</given-names></name><name><surname>Mariani</surname><given-names>T</given-names></name>, <etal>et al</etal></person-group>: <article-title>Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology</article-title>. J Clin Oncol <volume>20</volume>:<fpage>2376</fpage>-<lpage>2381</lpage>, <year>2002</year></mixed-citation>
              </ref>
              <ref id="b5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Bacik</surname><given-names>J</given-names></name><name><surname>Murphy</surname><given-names>BA</given-names></name>, <etal>et al</etal></person-group>: <article-title>Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma</article-title>. J Clin Oncol <volume>20</volume>:<fpage>289</fpage>-<lpage>296</lpage>, <year>2002</year></mixed-citation>
              </ref>
              <ref id="b6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fyfe</surname><given-names>G</given-names></name><name><surname>Fisher</surname><given-names>RI</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name>, <etal>et al</etal></person-group>: <article-title>Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy</article-title>. J Clin Oncol <volume>13</volume>:<fpage>688</fpage>-<lpage>696</lpage>, <year>1995</year></mixed-citation>
              </ref>
              <ref id="b7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Upton</surname><given-names>MP</given-names></name><name><surname>Parker</surname><given-names>RA</given-names></name><name><surname>Youmans</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>: <article-title>Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy</article-title>. J Immunother <volume>28</volume>:<fpage>488</fpage>-<lpage>495</lpage>, <year>2005</year></mixed-citation>
              </ref>
              <ref id="b8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDermott</surname><given-names>DF</given-names></name><name><surname>Lee</surname><given-names>J-L</given-names></name><name><surname>Bjarnason</surname><given-names>GA</given-names></name>, <etal>et al</etal></person-group>: <article-title>First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A</article-title>. J Clin Oncol 2020 (suppl; abstr 5069)</mixed-citation>
              </ref>
              <ref id="b9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Giorgi</surname><given-names>U</given-names></name><name><surname>Carteni</surname><given-names>G</given-names></name><name><surname>Giannarelli</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>: <article-title>Safety and efficacy of nivolumab for metastatic renal cell carcinoma: Real-world results from an expanded access programme</article-title>. BJU Int <volume>123</volume>:<fpage>98</fpage>-<lpage>105</lpage>, <year>2019</year></mixed-citation>
              </ref>
              <ref id="b10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koshkin</surname><given-names>VS</given-names></name><name><surname>Barata</surname><given-names>PC</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name>, <etal>et al</etal></person-group>: <article-title>Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma</article-title>. J Immunother Cancer <volume>6</volume>:<fpage>9</fpage>, <year>2018</year></mixed-citation>
              </ref>
              <ref id="b11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGregor</surname><given-names>BA</given-names></name><name><surname>McKay</surname><given-names>RR</given-names></name><name><surname>Braun</surname><given-names>DA</given-names></name>, <etal>et al</etal></person-group>: <article-title>Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and/or sarcomatoid features</article-title>. J Clin Oncol <volume>38</volume>:<fpage>63</fpage>-<lpage>70</lpage>, <year>2020</year></mixed-citation>
              </ref>
              <ref id="b12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chahoud</surname><given-names>J</given-names></name><name><surname>Msaouel</surname><given-names>P</given-names></name><name><surname>Campbell</surname><given-names>MT</given-names></name>, <etal>et al</etal></person-group>: <article-title>Nivolumab for the treatment of patients with metastatic non-clear cell renal cell carcinoma (nccRCC): A single-institutional experience and literature meta-analysis</article-title>. Oncologist, <volume>25</volume>:<fpage>252</fpage>-<lpage>258</lpage>, <year>2019</year></mixed-citation>
              </ref>
              <ref id="b13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>AJ</given-names></name><name><surname>Halabi</surname><given-names>S</given-names></name><name><surname>Eisen</surname><given-names>T</given-names></name>, <etal>et al</etal></person-group>: <article-title>Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): A multicentre, open-label, randomised phase 2 trial</article-title>. Lancet Oncol <volume>17</volume>:<fpage>378</fpage>-<lpage>388</lpage>, <year>2016</year></mixed-citation>
              </ref>
              <ref id="b14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tannir</surname><given-names>NM</given-names></name><name><surname>Jonasch</surname><given-names>E</given-names></name><name><surname>Albiges</surname><given-names>L</given-names></name>, <etal>et al</etal></person-group>: <article-title>Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): A randomized multicenter phase 2 trial</article-title>. Eur Urol <volume>69</volume>:<fpage>866</fpage>-<lpage>874</lpage>, <year>2016</year></mixed-citation>
              </ref>
              <ref id="b15">
                <label>15.</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author">KEYTRUDA® (pembrolizumab) for Injection, for Intravenous Use</person-group>. <publisher-loc>Whitehouse Station, NJ</publisher-loc>, <publisher-name>Merck Sharp &amp; Dohme Corp</publisher-name>, <year>2020</year></mixed-citation>
              </ref>
              <ref id="b16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baxi</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>A</given-names></name><name><surname>Gennarelli</surname><given-names>RL</given-names></name>, <etal>et al</etal></person-group>: <article-title>Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: Systematic review and meta-analysis</article-title>. BMJ <volume>360</volume>:<fpage>k793</fpage>, <year>2018</year></mixed-citation>
              </ref>
              <ref id="b17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>PF</given-names></name><name><surname>Ma</surname><given-names>JX</given-names></name><name><surname>Wang</surname><given-names>FX</given-names></name>, <etal>et al</etal></person-group>: <article-title>Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: A systematic review and meta-analysis</article-title>. Ther Clin Risk Manag <volume>13</volume>:<fpage>1259</fpage>-<lpage>1271</lpage>, <year>2017</year></mixed-citation>
              </ref>
              <ref id="b18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varricchi</surname><given-names>G</given-names></name><name><surname>Galdiero</surname><given-names>MR</given-names></name><name><surname>Marone</surname><given-names>G</given-names></name>, <etal>et al</etal></person-group>: <article-title>Cardiotoxicity of immune checkpoint inhibitors</article-title>. ESMO Open <volume>2</volume>:<fpage>e000247</fpage>, <year>2017</year></mixed-citation>
              </ref>
              <ref id="b19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricketts</surname><given-names>CJ</given-names></name><name><surname>De Cubas</surname><given-names>AA</given-names></name><name><surname>Fan</surname><given-names>H</given-names></name>, <etal>et al</etal></person-group>: <article-title>The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma</article-title>. <source>Cell Rep</source><volume>23</volume>:<fpage>313</fpage>-<lpage>326.e5</lpage>, <year>2018</year><pub-id pub-id-type="pmid">29617669</pub-id></mixed-citation>
              </ref>
              <ref id="b20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papanikolaou</surname><given-names>D</given-names></name><name><surname>Ioannidou</surname><given-names>P</given-names></name><name><surname>Koukourikis</surname><given-names>P</given-names></name>, <etal>et al</etal></person-group>: <article-title>Systemic therapy for chromophobe renal cell carcinoma: A systematic review</article-title>. Urol Oncol <volume>38</volume>:<fpage>137</fpage>-<lpage>149</lpage>, <year>2020</year></mixed-citation>
              </ref>
              <ref id="b21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choueiri</surname><given-names>TK</given-names></name><name><surname>Fay</surname><given-names>AP</given-names></name><name><surname>Gray</surname><given-names>KP</given-names></name>, <etal>et al</etal></person-group>: <article-title>PD-L1 expression in nonclear-cell renal cell carcinoma</article-title>. Ann Oncol <volume>25</volume>:<fpage>2178</fpage>-<lpage>2184</lpage>, <year>2014</year></mixed-citation>
              </ref>
              <ref id="b22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erlmeier</surname><given-names>F</given-names></name><name><surname>Hartmann</surname><given-names>A</given-names></name><name><surname>Autenrieth</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>: <article-title>PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?</article-title> Med Oncol <volume>33</volume>:<fpage>120</fpage>, <year>2016</year></mixed-citation>
              </ref>
              <ref id="b23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motoshima</surname><given-names>T</given-names></name><name><surname>Komohara</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>: <article-title>PD-L1 expression in papillary renal cell carcinoma</article-title>. BMC Urol <volume>17</volume>:<fpage>8</fpage>, <year>2017</year></mixed-citation>
              </ref>
              <ref id="b24">
                <label>24.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chipollini</surname><given-names>J</given-names></name><name><surname>Azizi</surname><given-names>M</given-names></name><name><surname>Peyton</surname><given-names>CC</given-names></name>, <etal>et al</etal></person-group>: <article-title>Implications of programmed death ligand-1 positivity in non-clear cell renal cell carcinoma</article-title>. J Kidney Cancer VHL <volume>5</volume>:<fpage>6</fpage>-<lpage>13</lpage>, <year>2018</year></mixed-citation>
              </ref>
              <ref id="b25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Peng</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>H</given-names></name>, <etal>et al</etal></person-group>: <article-title>Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: A meta-analysis based on 1863 individuals</article-title>. Clin Exp Med <volume>18</volume>:<fpage>165</fpage>-<lpage>175</lpage>, <year>2018</year></mixed-citation>
              </ref>
              <ref id="b26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rini</surname><given-names>BI</given-names></name><name><surname>Plimack</surname><given-names>ER</given-names></name><name><surname>Stus</surname><given-names>V</given-names></name>, <etal>et al</etal></person-group>: <article-title>Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma</article-title>. N Engl J Med <volume>380</volume>:<fpage>1116</fpage>-<lpage>1127</lpage>, <year>2019</year></mixed-citation>
              </ref>
              <ref id="b27">
                <label>27.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rini</surname><given-names>BI</given-names></name><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Powles</surname><given-names>T</given-names></name>, <etal>et al</etal></person-group>: <article-title>Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis</article-title>. J Clin Oncol <volume>37</volume>, <year>2019</year> (<comment>suppl; abstr 4512</comment>)</mixed-citation>
              </ref>
              <ref id="b28">
                <label>28.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choueiri</surname><given-names>TK</given-names></name><name><surname>Albiges</surname><given-names>L</given-names></name><name><surname>Haanen</surname><given-names>JBAG</given-names></name>, <etal>et al</etal></person-group>: <article-title>Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)</article-title>. J Clin Oncol <volume>37</volume>, <year>2019</year> (<comment>suppl; abstr 101</comment>)</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
